The FDA has accepted for review Urovant Sciences’ New Drug Application for once-daily 75 mg vibegron for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
The FDA has accepted for review Urovant Sciences’ New Drug Application (NDA) for once-daily 75 mg vibegron for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
The NDA has been assigned a Prescription Drug User Fee Act goal date of Dec. 26, 2020. In addition, the FDA has indicated that it is not currently planning to hold an Advisory Committee meeting to discuss the application, Urovant Sciences said.
Vibegron is an oral, once-daily small molecule beta-3 agonist that is being evaluated for OAB. Urovant Sciences reported positive data from the vibegron 12-week, phase III pivotal EMPOWUR study and demonstrated favorable longer-term efficacy, safety, and tolerability in a 40-week extension study.
Results from EMPOWUR were published in the Journal of Urology (Feb. 18, 2020 [Epub ahead of print]). The double-blind, placebo-controlled 12-week trial, in patients with OAB, studied vibegron 75 mg once-daily compared to placebo and included an active control. In the trial, vibegron achieved rapid onset of action at 2 weeks in both co-primary endpoints and daily urgency episodes, and statistically significant efficacy was maintained at all timepoints measured through the end of the study.
Vibegron is also being evaluated for treatment of OAB in men with BPH and for abdominal pain associated with irritable bowel syndrome.
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
UK study of AI-based software for prostate cancer detection expands
July 22nd 2024"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.